Freenome Vallania Study Additional Inclusion & Exclusion Criteria

Ovarian Cancer

Subject must be diagnosed with histologically-confirmed serous or endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer, or have a presumptive diagnosis of or high clinical suspicion for the same by imaging (e.g., CT, MRI, PET or ultrasound) and have not yet received any cancer treatment (including but not limited to surgery, chemotherapy, and/or radiation)

Pancreatic Cancer Subject must be diagnosed with pathologically-confirmed pancreatic cancer (i.e., adenocarcinoma, acinar cell carcinoma, cystadenocarcinomas, and mucinous cystic neoplasms) or have a presumptive diagnosis of or high clinical suspicion for the same by imaging (e.g., CT, MRI, PET or ultrasound) and have not yet received any cancer treatment (including but not limited to surgery, chemotherapy, and/or radiation)

Prostate Subjects must be diagnosed with prostate cancer, and have not yet received any cancer treatment (including but not limited to surgery, chemotherapy, biologic therapy, immunotherapy, and/or radiation therapy)

Thyroid Received Subjects must be diagnosed with cytologically-confirmed primary thyroid carcinoma and have not yet received any cancer treatment (including but not limited to surgery, chemotherapy, and/or radiation therapy)

Uterine Subjects must be diagnosed with histologically-confirmed uterine endometrioid carcinoma, uterine carcinosarcoma, or high grade serous carcinoma, or have a presumptive diagnosis of or high clinical suspicion of the above by imaging (e.g., CT or MRI) which will then be confirmed, and have not yet received any cancer treatment (including but not limited to surgery, chemotherapy, and/or radiation therapy)

Financial Budget Sample:

$1,500 per patient

$300 per Investigator

$1,200 site fees*

*Pre CSHRI fee